Literature DB >> 11579460

Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1.

S Scheil1, S Brüderlein, T Liehr, H Starke, J Herms, M Schulte, P Möller.   

Abstract

Cytogenetic information on chordomas is rudimentary and restricted to GTG-banding analysis of 26 cases worldwide. In this study, we present the chromosomal imbalances detected in a series of 16 chordomas (10 sacrococcyeal, five sphenooccipital, and one spinal) from 13 patients using comparative genomic hybridization (CGH) and fluorescence in situ hybridization (FISH). On average, 3.2 losses and 4.2 gains were detected per tumor. The most common DNA copy number alterations were losses on chromosomal arms 3p (50%) and 1p (44%). Losses of 3p were detected in five of seven primary chordomas. Therefore, the loss of 3p might be an early event in chordoma genesis. The most common gains involved 7q (69%), 20 (50%), 5q (38%), and 12q (38%). Additionally, we raised the first human chordoma cell line, U-CH1, from a recurrence of a sacral chordoma. U-CH1 and its parent tumor had almost the same CGH profile. According to GTG-banding and multicolor FISH, U-CH1 has the following clonal chromosomal abnormalities: der(1)t(1;22), del(4), +del(5), +del(6), +7, del(9), del(10), +der(20)t(10;20), +21. Thus, the novel permanent human chordoma cell line U-CH1 has chordoma-typical cytogenetic aberrations. Our data suggest that tumor suppressor genes or mismatch repair genes (located at 1p31 and 3p14) and oncogenes (located in 7q36) might be involved in chordoma genesis. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11579460     DOI: 10.1002/gcc.1184

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  69 in total

1.  Establishment and characterization of a primary human chordoma xenograft model.

Authors:  I-Mei Siu; Vafi Salmasi; Brent A Orr; Qi Zhao; Zev A Binder; Christine Tran; Masaru Ishii; Gregory J Riggins; Christine L Hann; Gary L Gallia
Journal:  J Neurosurg       Date:  2012-01-27       Impact factor: 5.115

Review 2.  Current therapeutic options and novel molecular markers in skull base chordomas.

Authors:  Filippo Gagliardi; Nicola Boari; Paola Riva; Pietro Mortini
Journal:  Neurosurg Rev       Date:  2011-10-18       Impact factor: 3.042

3.  MicroRNA-1 (miR-1) inhibits chordoma cell migration and invasion by targeting slug.

Authors:  Eiji Osaka; Xiaoqian Yang; Jacson K Shen; Pei Yang; Yong Feng; Henry J Mankin; Francis J Hornicek; Zhenfeng Duan
Journal:  J Orthop Res       Date:  2014-04-24       Impact factor: 3.494

4.  The role of TNF-α in chordoma progression and inflammatory pathways.

Authors:  Sukru Gulluoglu; Emre Can Tuysuz; Mesut Sahin; Cumhur Kaan Yaltirik; Aysegul Kuskucu; Ferda Ozkan; Altay Burak Dalan; Fikrettin Sahin; Ugur Ture; Omer Faruk Bayrak
Journal:  Cell Oncol (Dordr)       Date:  2019-06-07       Impact factor: 6.730

5.  The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas.

Authors:  Craig Horbinski; Gerard J Oakley; Kathleen Cieply; Geeta S Mantha; Marina N Nikiforova; Sanja Dacic; Raja R Seethala
Journal:  Arch Pathol Lab Med       Date:  2010-08       Impact factor: 5.534

6.  Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma.

Authors:  Jason M Davies; Aaron E Robinson; Cynthia Cowdrey; Praveen V Mummaneni; Gregory S Ducker; Kevan M Shokat; Andrew Bollen; Byron Hann; Joanna J Phillips
Journal:  J Neurosurg       Date:  2013-11-29       Impact factor: 5.115

7.  MGMT promoter methylation status in clival chordoma.

Authors:  Gianluca Marucci; Luca Morandi; Diego Mazzatenta; Giorgio Frank; Ernesto Pasquini; Maria Pia Foschini
Journal:  J Neurooncol       Date:  2014-04-26       Impact factor: 4.130

8.  Characterization of the endolysosomal system in human chordoma cell lines: is there a role of lysosomes in chemoresistance of this rare bone tumor?

Authors:  Dagmar Kolb-Lenz; Robert Fuchs; Birgit Lohberger; Ellen Heitzer; Katharina Meditz; Dominique Pernitsch; Elisabeth Pritz; Andrea Groselj-Strele; Andreas Leithner; Bernadette Liegl-Atzwanger; Beate Rinner
Journal:  Histochem Cell Biol       Date:  2018-05-03       Impact factor: 4.304

9.  An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma.

Authors:  Andrew C Nelson; Nischalan Pillay; Stephen Henderson; Nadège Presneau; Roberto Tirabosco; Dina Halai; Fitim Berisha; Paul Flicek; Derek L Stemple; Claudio D Stern; Fiona C Wardle; Adrienne M Flanagan
Journal:  J Pathol       Date:  2012-09-26       Impact factor: 7.996

10.  Update on the cytogenetics and molecular genetics of chordoma.

Authors:  Lidia Larizza; Pietro Mortini; Paola Riva
Journal:  Hered Cancer Clin Pract       Date:  2005-02-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.